Suppr超能文献

经皮二尖瓣修复术

[Pecutaneous mitral valve repair].

作者信息

Pedrazzini Giovanni B, Sürder Daniel, Faletra Franco, Moccetti Ticiano

机构信息

Fondazione Cardiocentro Ticino, Lugano.

出版信息

Praxis (Bern 1994). 2013 Feb 27;102(5):265-71. doi: 10.1024/1661-8157/a001199.

Abstract

Over four million Europeans and a similar number Americans suffer from significant mitral regurgitation (MR). Approximately 250,000 new patients are diagnosed with the disease annually. The disorder generally evolves insidiously over many years because the heart compensates for the regurgitant volume by left atrial enlargement, left ventricular (LV) volume overload, and progressive (LV) dilatation. The most common causes of MR include ischemic heart disease, non-ischemic heart disease, and valve degeneration. Mitral valve surgery has long been the only treatment available with proven efficacy for MR. It alleviates clinical symptoms and prevents ventricular dilatation and heart failure, or attenuates further progression of this process. Surgical valve repair significantly improves clinical outcomes compared with valve replacement, reducing mortality by approximately 70%. However, patients with heart failure have both higher acute risk and significant rates of late MR recurrence after surgical repair of ischemic MR. Recently, a number of percutaneous modalities of mitral valve repair have been developed. Most of these techniques are still at early stages of clinical evaluation. The MitraClip System consists of a percutaneous edge-to-edge attachemnt system that mimics the surgical procedure. This technique creates a bridge between the anterior and posterior leaflet by means of a clip deployed through trans-septal catheterization. The growing experience show that percutaneous edge-to-edge repair using the MitraClip system is feasible, safe and, in overall, effective, with very promising clinical results when performed in carefully selected patients, The new technique does not represent a general alternative to conventional surgical valve repair, which remains the gold standard particularly in the patients with degenerative MR. However, it offers a valid option in patients unsuitable for surgery and those with functional MR secondary to advanced heart failure, where the surgical approach still remains empiric.

摘要

超过400万欧洲人和数量相近的美国人患有严重的二尖瓣反流(MR)。每年约有25万新患者被诊断出患有这种疾病。该病症通常在多年内隐匿发展,因为心脏通过左心房扩大、左心室(LV)容量超负荷和渐进性(LV)扩张来代偿反流容积。MR最常见的病因包括缺血性心脏病、非缺血性心脏病和瓣膜退变。长期以来,二尖瓣手术一直是唯一被证实对MR有效的治疗方法。它可缓解临床症状,预防心室扩张和心力衰竭,或减缓这一过程的进一步发展。与瓣膜置换相比,手术瓣膜修复能显著改善临床结局,将死亡率降低约70%。然而,心力衰竭患者在缺血性MR手术修复后,急性风险更高,且晚期MR复发率也很高。最近,已开发出多种经皮二尖瓣修复方法。其中大多数技术仍处于临床评估的早期阶段。MitraClip系统是一种经皮缘对缘附着系统,模仿了外科手术过程。该技术通过经房间隔导管插入置入夹子,在二尖瓣前后叶之间形成一座桥。越来越多的经验表明,使用MitraClip系统进行经皮缘对缘修复是可行、安全的,总体上也是有效的,在精心挑选的患者中进行时临床效果非常可观。这项新技术并非传统外科瓣膜修复的普遍替代方法,传统外科瓣膜修复仍是金标准,尤其对于退行性MR患者而言更是如此。然而,它为不适合手术的患者以及继发于晚期心力衰竭的功能性MR患者提供了一种有效的选择,在这些情况下,手术方法仍属经验性方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验